This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
Journal of Hematology & Oncology Open Access 01 August 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.
Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158–1164.
Mesa RA, Tefferi A, Li CY, Steensma DP . Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 2006; 20: 2063–2064.
Lancet JE, List AF, Moscinski LC . Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007; 21: 586–588.
Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139–4141.
Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746–755.
Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI . Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006; 30: 849–858.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tefferi, A., Lasho, T., Mesa, R. et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 21, 1827–1828 (2007). https://doi.org/10.1038/sj.leu.2404711
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404711
This article is cited by
-
Management of Myelofibrosis-Related Cytopenias
Current Hematologic Malignancy Reports (2018)
-
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Leukemia (2018)
-
Managing patients with myelofibrosis and low platelet counts
Annals of Hematology (2017)
-
Pharmacotherapy of Myelofibrosis
Drugs (2017)
-
Novel myelofibrosis treatment strategies: potential partners for combination therapies
Leukemia (2014)